Overview

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

Status:
RECRUITING
Trial end date:
2028-01-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease
Phase:
PHASE2
Details
Lead Sponsor:
Belite Bio, Inc